Taking stock of the drug industry, from the lab to the medicine chestMarch 3, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | After Canada required pharma to pay fees, drug agency recommended coverage more often The likelihood that the Drug Agency would recommend jurisdictions fund coverage of medicines was six times higher for all drugs, other than cancer drugs. By Ed Silverman STAT+ | AbbVie steps into the obesity drug race, licensing medicine from Danish firm The deal includes a $350 million upfront payment and potentially $1.9 billion depending on certain milestones being met. By Andrew Joseph HHS review of a vaccine contract sparks worries about preparedness for a potential bird flu pandemic Trump administration review causes concern this could be a prelude to cancelling a contract seen as critical for H5N1 pandemic preparedness By Helen Branswell Meet the research teams facing off in STAT Madness 2025. Voting is now open Here are the teams competing in STAT Madness 2025, our tournament-style competition celebrating innovation in health and medicine. Voting now open. By STAT Staff STAT+ | Top HHS spokesman abruptly resigns after reports of tensions with RFK Jr. and his team Thomas Corry didn't provide a public explanation for his decision but a source said it followed tensions with Secretary RFK Jr. and his team. By Sarah Owermohle More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments